Although the issue seems unlikely to be related to the study drug, Regulus Therapeutics Inc.'s mid-stage hepatitis C candidate RG-101 has been placed on clinical hold by FDA after a second patient presented a serious adverse event of jaundice.
It's a potentially serious setback for the clinical-stage microRNA specialist, which is trying to elbow into the competitive HCV space with an agent